Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Pfizer has several products with fast-rising sales. Nurtec ODT and Padcev especially stand out. Its pipeline is also promising: 115 programs in clinical development, 32 of which are in late-stage ...

The company entered the oral peptides market with NURTEC ODT, a CGRP receptor antagonist used to treat episodic migraines. Pfizer's pipeline appears robust; one notable drug in development is ...

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks ...

If a company files for Chapter 7 bankruptcy, that means it's heading for liquidation, in which assets are sold off to pay creditors.